Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise in shrinking fatty liver

NCT ID NCT06482112

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medication called efinopegdutide in 124 adults with fatty liver disease (also called MASLD). The goal was to see if taking the drug every two weeks or every week could safely reduce liver fat. After 28 weeks, the drug helped lower liver fat, and researchers also checked for side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

124 people

The number who actually took part.

Started

Jul 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has body mass index (BMI) ≥25 kg/m\^2 (≥23 kg/m\^2 for Asian participants) AND has stable weight, defined as ≤5% gain or loss of body weight for at least 3 months before screening * Has no history of type 2 diabetes mellitus (T2DM) OR has a history of T2DM with a glycated hemoglobin (A1C) ≤9% AND the T2DM is controlled by diet or stable doses of oral antihyperglycemic agents (AHAs) Exclusion Criteria: The main exclusion criteria include but are not limited to the following * Has a history or evidence of chronic liver disease other than Metabolic dysfunction-associated steatotic liver disease (MASLD) or Metabolic dysfunction-associated steatohepatitis (MASH) * Has evidence of decompensated liver disease including, but not limited to ascites, esophageal or gastric variceal bleeding, hepatocellular carcinoma, hepatic encephalopathy, splenomegaly, or spontaneous bacterial peritonitis * Has a history of pancreatitis * Has a history of type 1 diabetes mellitus (T1DM), diabetic ketoacidosis, or diabetes secondary to pancreatectomy. * Has symptomatic hyperglycemia * Has a history of a bariatric surgical procedure ≤5 years before Screening or a known clinically significant gastric emptying abnormality * Has a history of obesity with a known secondary cause * Has significant systemic or major illnesses, including recent (≤6 months before Screening) onset of events of congestive heart failure, unstable angina, myocardial infarction, arterial revascularization, stroke, or transient ischemic attack * Is unable to have Magnetic Resonance Imaging-Estimated Proton Density Fat Fraction (MRI-PDFF) due to: Claustrophobia to a degree that prevents tolerance of an MRI-PDFF scanning procedure. Note: Sedation is permitted, at the discretion of the investigator; Metallic implants that prevent MRI-PDFF examination; Exceeds the body habitus and/or weight limitations for the MRI scanner

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Liver disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

liver disorder metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver disease Metabolic dysfunction-associated steatotic liver disease Non-alcoholic fatty liver disease Nonalcoholic fatty liver disease

Contacts and locations

Locations

  • AGA Clinical Trials ( Site 0274)

    Hialeah, Florida, 33012, United States

  • Acclaim Clinical Research ( Site 0241)

    San Diego, California, 92120, United States

  • American Research Corporation ( Site 0234)

    San Antonio, Texas, 78215, United States

  • Arizona Liver Health ( Site 0211)

    Tucson, Arizona, 85712, United States

  • Basil Clinical ( Site 0246)

    Inwood, New York, 11096, United States

  • California Liver Research Institute ( Site 0216)

    Pasadena, California, 91105, United States

  • Clinical Trials of Texas, LLC-Clinical Research ( Site 0252)

    San Antonio, Texas, 78229, United States

  • Del Sol Research Management, LLC ( Site 0209)

    Tucson, Arizona, 85715, United States

  • Excel Clinical Research, LLC ( Site 0200)

    Las Vegas, Nevada, 89109, United States

  • Excel Medical Clinical Trials ( Site 0268)

    Boca Raton, Florida, 33434, United States

  • Floridian Clinical Research, LLC ( Site 0208)

    Miami Lakes, Florida, 33016, United States

  • Gastroenterology and Liver Institute ( Site 0263)

    Escondido, California, 92025, United States

  • Homestead Associates in Research, Inc. ( Site 0243)

    Homestead, Florida, 33033, United States

  • Houston Research Institute ( Site 0221)

    Houston, Texas, 77079, United States

  • Impact Research Institute ( Site 0227)

    Waco, Texas, 76710, United States

  • Klinical Investigations Group-Clinical Research ( Site 0100)

    San Juan, 00909, Puerto Rico

  • Lucas Research, Inc ( Site 0204)

    Morehead City, North Carolina, 28557, United States

  • Neoclinical Research ( Site 0275)

    Hialeah, Florida, 33016, United States

  • Olympus Family Medicine/CCT Research ( Site 0266)

    Holladay, Utah, 84117, United States

  • Om Research LLC ( Site 0207)

    Camarillo, California, 93012, United States

  • Pan American Center for Oncology Trials - Ciudadela ( Site 0101)

    San Juan, 00909, Puerto Rico

  • Pinnacle Clinical Research ( Site 0203)

    Austin, Texas, 78757, United States

  • Pinnacle Clinical Research-Clinical Research Coordination ( Site 0229)

    San Antonio, Texas, 78229, United States

  • Pinnacle Clinical Research-Corpus Christi ( Site 0267)

    Corpus Christi, Texas, 78404, United States

  • San Juan Bautista School of Medicine - Clinical Research Unit ( Site 0104)

    Caguas, 00726, Puerto Rico

  • South Ogden Family Medicine/ CCT Research ( Site 0255)

    South Ogden, Utah, 84405, United States

  • South Texas Research Institute ( Site 0226)

    Edinburg, Texas, 78539, United States

  • Southeast Clinical Research Center ( Site 0223)

    Dalton, Georgia, 30720, United States

  • Texas Clinical Research Institute ( Site 0230)

    Arlington, Texas, 76012, United States

  • The Institute for Liver Health II dba Arizona Clinical Trial-The Institute for Liver Health ( Site 0

    Chandler, Arizona, 85224, United States

  • The Institute for Liver Health II dba Arizona Liver Health - Peoria ( Site 0224)

    Peoria, Arizona, 85381, United States

  • The Machuca Foundation ( Site 0218)

    Las Vegas, Nevada, 89101, United States

  • Velocity Clinical Research Rockville ( Site 0245)

    Rockville, Maryland, 20854, United States

  • Velocity Clinical Research, Austin ( Site 0201)

    Austin, Texas, 78759, United States

  • Velocity Clinical Research, Gardena ( Site 0235)

    Gardena, California, 90247, United States

  • Velocity Clinical Research, Huntington Park ( Site 0210)

    Huntington Park, California, 90255, United States

  • Velocity Clinical Research, Panorama City ( Site 0228)

    Van Nuys, California, 91405, United States

  • Velocity Clinical Research, Santa Ana ( Site 0250)

    Santa Ana, California, 92704, United States

  • Zenos Clinical Research ( Site 0240)

    Dallas, Texas, 75230, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.